Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426491 · ClinicalTrials.gov registry record · Phase 3
Misoprostol for Non-Viable Pregnancies
A Phase 3 study, sponsored by Madigan Army Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00426491: Completed Phase 3 study, sponsored by Madigan Army Medical Center.
NCT00426491 is a Phase 3 study that has completed, run by Madigan Army Medical Center. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426491, a Phase 3 study, has completed, sponsored by Madigan Army Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects.
Interventions
- DRUG Misoprostol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-03 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
What the finished NCT00426491 record still lists
NCT00426491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Misoprostol is the first listed.
NCT00426491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00426491 about?
NCT00426491 is a clinical study titled "Misoprostol for Non-Viable Pregnancies". The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documen...
What is the current status of trial NCT00426491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 1999-03. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00426491?
The interventions under investigation include: Misoprostol (DRUG).
Who is sponsoring clinical trial NCT00426491?
This trial is sponsored by Madigan Army Medical Center, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00426491's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia